IGF2BP3 Expression Correlates With Poor Prognosis in Esophageal Squamous Cell Carcinoma

Wakita, Akiyuki; Motoyama, Satoru; Sato, Yusuke; Nagaki, Yushi; Fujita, Hiromu; Terata, Kaori; Imai, Kazuhiro; Maeda, Eri; Minamiya, Yoshihiro

doi:10.1016/j.jss.2020.10.024

Cited by 14 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IGF2BP3 expression was also shown to be correlated with the clinical stage in urachal carcinoma and ovarian clear cell carcinoma 26 , 27 and associated with lymphatic invasion and histological grade, 28 lesion depth 29 and poor OS and disease‐free survival. 30 , 31 This study only found a positive relationship between IGF2BP3 expression and distant metastasis after initial treatment in NPC. Furthermore, this study showed the negative link between OS, DMFS and IGF2BP3 protein levels.…”

Section: Discussionmentioning

confidence: 74%

See 1 more Smart Citation

IGF2BP3 promotes cell metastasis and is associated with poor patient survival in nasopharyngeal carcinoma

Guo

Peng

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) has obvious geographical distribution characteristics and is commonly diagnosed in certain regions of east and southeast Asia, such as China. 1 In particular, NPC mainly occurs in the southern provinces of China and ranks first among head and neck malignant tumours in Fujian. Treatment with induction chemotherapy plus concurrent chemoradiotherapy has improved the 5-year overall survival (OS) of patients with stage III-IVB NPC to 86%, while 22% of the patients develop locoregional or distant failures. 2 Therefore, it is necessary to clarify the underlying mechanisms of NPC metastasis and identify novel prognostic factors and targets for NPC.Insulin-like growth factor 2 mRNAs binding protein 3 (IGF2BP3) is a highly conserved member of the insulin-like growth factor 2 mRNAs binding protein family. IGF2BP3 functions as a post-transcriptional

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 99%

IGF2BP3 promotes cell metastasis and is associated with poor patient survival in nasopharyngeal carcinoma

Guo

Peng

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…In this study, the expression patterns, prognostic values and effects on the TIME of m6A RNA methylation regulators in ESCC were explored. The expression levels of m6A "writers" (METTL3 and WTAP) and "readers" (i.e., IGF2BP3, YTHDF1, HNRNPA2B1 and HNRNPC) in ESCC were significantly higher than those in normal tissues, and elevated expression levels of 2 genes (METTL3 and IGF2BP3) have been reported to be an independent prognostic factor for ESCC patients (26,27); other genes have not been studied. In STRING, a protein-protein interaction (PPI) network composed of 20 m6A RNA methylation regulators was generated, and the biological functions involved in the regulators were preliminarily analysed through GO functional annotation.…”

Section: Discussionmentioning

confidence: 98%

“…Another study showed that the high expression of HNRNPC is significantly related to the poor OS of patients with lung adenocarcinoma, and it is likely to be an oncogene in patients with lung adenocarcinoma and breast cancer (35,36). IGF2BP3 is highly expressed in many tumors, including ESCC, lung adenocarcinoma, colon cancer, and gastric cancer, and leads to poor prognosis (26,(37)(38)(39). There is no research report on KIAA1429 in ESCC, but some scholars pointed out that KIAA1429 can promote the progression of liver cancer, breast cancer and osteosarcoma, leading to poor prognosis (40)(41)(42).…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma

et al. 2021

View full text Add to dashboard Cite

BackgroundEsophageal squamous cell carcinoma (ESCC) is one of the most common cancer types and represents a threat to global public health. N6-Methyladenosine (m6A) methylation plays a key role in the occurrence and development of many tumors, but there are still few studies investigating ESCC. This study attempts to construct a prognostic signature of ESCC based on m6A RNA methylation regulators and to explore the potential association of these regulators with the tumor immune microenvironment (TIME).MethodsThe transcriptome sequencing data and clinical information of 20 m6A RNA methylation regulators in 453 patients with ESCC (The Cancer Genome Atlas [TCGA] cohort, n = 95; Gene Expression Omnibus [GEO] cohort, n = 358) were obtained. The differing expression levels of m6A regulators between ESCC and normal tissue were evaluated. Based on the expression of these regulators, consensus clustering was performed to investigate different ESCC clusters. PD-L1 expression, immune score, immune cell infiltration and potential mechanisms among different clusters were examined. LASSO Cox regression analysis was utilized to obtain a prognostic signature based on m6A RNA methylation modulators. The relationship between the risk score based on the prognostic signature and the TIME of ESCC patients was studied in detail.ResultsSix m6A regulators (METTL3, WTAP, IGF2BP3, YTHDF1, HNRNPA2B1 and HNRNPC) were observed to be significantly highly expressed in ESCC tissues. Two molecular subtypes (clusters 1/2) were determined by consensus clustering of 20 m6A modulators. The expression level of PD-L1 in ESCC tissues increased significantly and was significantly negatively correlated with the expression levels of YTHDF2, METL14 and KIAA1429. The immune score, CD8 T cells, resting mast cells, and regulatory T cells (Tregs) in cluster 2 were significantly increased. Gene set enrichment analysis (GSEA) shows that this cluster involves multiple hallmark pathways. We constructed a five-gene prognostic signature based on m6A RNA methylation, and the risk score based on the prognostic signature was determined to be an independent prognostic indicator of ESCC. More importantly, the prognostic value of the prognostic signature was verified using another independent cohort. m6A regulators are related to TIME, and their copy-number alterations will dynamically affect the number of tumor-infiltrating immune cells.ConclusionOur study established a strong prognostic signature based on m6A RNA methylation regulators; this signature was able to accurately predict the prognosis of ESCC patients. The m6A methylation regulator may be a key mediator of PD-L1 expression and immune cell infiltration and may strongly affect the TIME of ESCC.

show abstract

“…Nonetheless, all three IGF2BPs are highly expressed and function as independent prognostic factors in a variety of cancers, including lung cancer 89 , 90 , liver cancer 91 - 93 , breast cancer 94 , 95 , colorectal cancer 96 - 98 , pancreatic cancer 99 - 101 , prostate cancer 102 , bladder cancer 103 - 105 , thyroid cancer 106 - 108 , gastric cancer 109 , 110 , renal cell carcinoma 111 , ovarian cancer 112 , 113 , esophageal squamous cell carcinoma 114 , 115 , acute myeloid leukemia 116 . In addition to the high expression of the IGF2BPs itself, intercellular communication factors, such as tumor-secreted extracellular vesicles (EVs), can maintain the stability of IGF2BPs in cells to promote the development of cancer.…”

Section: The Oncogenic Role Of Igf2bps In Cancermentioning

confidence: 99%

The role of Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) as m⁶A readers in cancer

Sun¹,

Cao²,

Du³

et al. 2022

Int. J. Biol. Sci.

View full text Add to dashboard Cite

RNA can be modified by over 170 types of distinct chemical modifications, and the most abundant internal modification of mRNA in eukaryotes is N6-methyladenosine (m 6 A). The m 6 A modification accelerates mRNA process, including mRNA splicing, translation, transcript stability, export and decay. m 6 A RNA modification is installed by methyltransferase-like proteins (writers), and potentially removed by demethylases (erasers), and this process is recognized by m 6 A-binding proteins (readers). Notably, alterations of m 6 A-modified proteins (writers, erasers and readers) are involved in the tumorigenesis, progression and metastasis. Importantly, the fate of m 6 A-methylated mRNA is mediated mostly through m 6 A readers, and among these readers, insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) are unique RNA-binding proteins (RBPs) that stabilize their targets mRNA via m 6 A modification. In this review, we update the writers, erasers and readers, and their cross-talks in m 6 A modification, and briefly discuss the oncogenic role of IGF2BPs in cancer. Most importantly, we mainly review the up-to-date knowledges of IGF2BPs (IGF2BP1/2/3) as m 6 A readers in an m 6 A-modified manner in cancer progression.

show abstract

IGF2BP3 Expression Correlates With Poor Prognosis in Esophageal Squamous Cell Carcinoma

Cited by 14 publications

References 36 publications

IGF2BP3 promotes cell metastasis and is associated with poor patient survival in nasopharyngeal carcinoma

IGF2BP3 promotes cell metastasis and is associated with poor patient survival in nasopharyngeal carcinoma

Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma

The role of Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) as m⁶A readers in cancer

Contact Info

Product

Resources

About

IGF2BP3 Expression Correlates With Poor Prognosis in Esophageal Squamous Cell Carcinoma

Cited by 14 publications

References 36 publications

IGF2BP3 promotes cell metastasis and is associated with poor patient survival in nasopharyngeal carcinoma

IGF2BP3 promotes cell metastasis and is associated with poor patient survival in nasopharyngeal carcinoma

Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma

The role of Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) as m6A readers in cancer

Contact Info

Product

Resources

About

The role of Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) as m⁶A readers in cancer